Want to see MTVA full AI Analyst Report?
Top Page
MetaVia
(NASDAQ:MTVA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(1.35% Upside)
Action:Reiterated
Date:08/10/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate developments are a partial offset due to encouraging clinical/pipeline milestones, but ongoing funding needs and limited valuation usefulness keep the overall score in the lower range.
Positive Factors
Low Leverage
Very low leverage limits fixed financial obligations and provides some balance-sheet resilience while the company funds clinical development. Positive equity offers a cushion, although continued losses could reduce that protection over time.
Negative Factors
Pre-Revenue Business Model
The absence of revenue means MetaVia has no operating inflows to offset development costs. Its financial outlook therefore depends heavily on successful clinical execution and eventual commercialization, both of which remain uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage limits fixed financial obligations and provides some balance-sheet resilience while the company funds clinical development. Positive equity offers a cushion, although continued losses could reduce that protection over time.
Read all positive factors
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.62M
Dividend YieldN/A
Average Volume (3M)3.42M
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth79.26%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.07
Shares Outstanding6,588,101
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.00Price Target Upside845.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
MetaVia Business Overview & Revenue Model
Company Description
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigation...
MetaVia Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.00K | -19.00K | -24.00K | -7.00K | -28.00K | -72.00K |
| EBITDA | -14.50M | -12.95M | -27.57M | -12.46M | -11.76M | -15.24M |
| Net Income | -14.45M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M |
Balance Sheet | ||||||
| Total Assets | 13.27M | 69.12M | 16.26M | 22.78M | 33.53M | 16.80M |
| Cash, Cash Equivalents and Short-Term Investments | 12.63M | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M |
| Total Debt | 177.00K | 210.00K | 136.00K | 203.00K | 0.00 | 71.00K |
| Total Liabilities | 6.45M | 63.79M | 8.33M | 6.10M | 11.78M | 2.20M |
| Stockholders Equity | 6.82M | 5.33M | 7.93M | 16.68M | 21.75M | 14.60M |
Cash Flow | ||||||
| Free Cash Flow | -15.84M | -15.70M | -24.72M | -10.85M | -11.71M | -15.14M |
| Operating Cash Flow | -15.84M | -15.70M | -24.71M | -10.80M | -11.71M | -15.13M |
| Investing Cash Flow | 0.00 | -2.00K | -8.00K | -50.00K | 8.00K | -586.00K |
| Financing Cash Flow | 10.88M | 9.96M | 18.30M | -80.00K | 28.68M | 22.03M |
MetaVia Technical Analysis
Positive
1.48
Price Trends
1.56
Positive
1.68
Negative
3.30
Negative
Market Momentum
-0.02
Negative
59.71
Neutral
62.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Positive. The current price of 1.48 is above the 20-day moving average (MA) of 1.47, below the 50-day MA of 1.56, and below the 200-day MA of 3.30, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 59.71 is Neutral, neither overbought nor oversold. The STOCH value of 62.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTVA.
MetaVia Risk Analysis
MetaVia disclosed 66 risk factors in its most recent earnings report. MetaVia reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MetaVia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $130.12M | -0.84 | -143.09% | ― | ― | -169.38% | |
54 Neutral | $89.38M | 2.12 | 68.56% | ― | -15.11% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.62M | -0.38 | -172.92% | ― | ― | 79.26% | |
46 Neutral | $16.48M | -0.27 | -67.42% | ― | ― | 57.48% |
* Healthcare Sector Average
MTVA
MetaVia
1.64
-5.29
-76.33%
PMN
ProMIS Neurosciences
15.36
1.63
11.91%
CTXR
Citius Pharmaceuticals
0.58
-0.75
-56.44%
RLYB
Rallybio
16.80
12.03
252.05%
KAPA
Kairos Pharma, Ltd.
0.23
-0.97
-80.67%
MetaVia Corporate Events
Business Operations and StrategyFinancial Disclosures
MetaVia Advances DA-1726 and Vanoglipel in Q2 Update
Positive
Aug 6, 2026
On August 6, 2026, MetaVia reported second-quarter 2026 financial results and detailed progress across its obesity and liver-disease pipelines, highlighted by all active patients reaching the 48 mg and 64 mg target doses in Part 3 of a 16-week Pha...
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Trial to Top Doses
Positive
Jul 9, 2026
On July 9, 2026, MetaVia announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial of DA-1726 for obesity have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. Part ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
MetaVia Announces $4 Million At-The-Market Stock Offering
Positive
Jul 2, 2026
On November 6, 2025, MetaVia Inc. entered into an at-the-market offering agreement with Ladenburg Thalmann Co. Inc., allowing the company to sell shares of its common stock from time to time through or to Ladenburg under Rule 415(a)(4) of the U.S...
Executive/Board ChangesShareholder MeetingsStock Split
MetaVia Shareholders Approve Equity Plan and Reverse Split
Neutral
Jun 8, 2026
At its virtual annual meeting of stockholders held on June 8, 2026, MetaVia Inc. secured shareholder approval for the first amendment to its 2022 Amended and Restated Equity Incentive Plan, increasing the pool of shares available for equity awards...
Business Operations and StrategyProduct-Related Announcements
MetaVia highlights obesity and metabolic pipeline advancements
Positive
Jun 8, 2026
On June 8, 2026, MetaVia reported new late-breaking clinical and preclinical data from the ADA 2026 Scientific Sessions in New Orleans, underscoring the potential differentiation of its obesity and metabolic pipeline. The Phase 1 multiple ascendin...
Business Operations and StrategyProduct-Related Announcements
MetaVia highlights promising Phase 1 obesity drug data
Positive
May 27, 2026
On May 27, 2026, MetaVia reported new higher-dose Phase 1 data for its dual GLP-1/glucagon agonist DA-1726 at the EASL Congress, showing up to 9.1% mean body-weight loss at Day 54 and nearly 10 cm waist reduction in obese but otherwise healthy adu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.